226 related articles for article (PubMed ID: 30995847)
1. Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.
Hrabovský Š; Folber F; Doubek M
Klin Onkol; 2019; 32(2):90-96. PubMed ID: 30995847
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of relapsed or refractory acute lymphoblastic leukemia].
Imai K
Rinsho Ketsueki; 2017; 58(10):1995-2003. PubMed ID: 28978841
[TBL] [Abstract][Full Text] [Related]
3. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
Sano H; Mochizuki K; Akaihata M; Kobayashi S; Ohto H; Kikuta A
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781393
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
Maino E; Bonifacio M; Scattolin AM; Bassan R
Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
7. The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL).
Sharplin KM; Marks DI
Leuk Lymphoma; 2022 Jun; 63(6):1292-1301. PubMed ID: 34991420
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
9. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
10. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020.
Rank CU; Schmiegelow K
Semin Hematol; 2020 Jul; 57(3):102-114. PubMed ID: 33256899
[TBL] [Abstract][Full Text] [Related]
11. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
12. Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium.
Wang ES; Jabbour EJ; Douer D
Clin Adv Hematol Oncol; 2016 Mar; 14(3 Suppl 4):1-23. PubMed ID: 27007406
[TBL] [Abstract][Full Text] [Related]
13. Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond.
Park J
J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1448-1450. PubMed ID: 31766014
[TBL] [Abstract][Full Text] [Related]
14. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed/refractory acute lymphoblastic leukemia.
Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Management of Acute Lymphoblastic Leukaemia.
Hodby KA; Marks DI
Curr Treat Options Oncol; 2020 Feb; 21(3):23. PubMed ID: 32095902
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
20. [Current status of cancer immunotherapy for relapsed/refractory acute lymphoblastic leukemia in children and adolescents in Japan].
Imai C
Rinsho Ketsueki; 2020; 61(6):673-681. PubMed ID: 32624542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
